The 2010 Health Care Reform Act: A Potential Opportunity to Advance Cancer Research by Taking Cancer Personally

The Patient Protection and Affordable Care Act of 2010 will have a profound influence on health care in the United States, including how we conduct cancer research and cancer care delivery. For this reason, oncologists and researchers must be intimately involved in the implementation and interpretation of this important legislation. A major goal of the Act is to improve access to affordable, quality health care. An important element in achieving this goal will be to learn from patients' experiences and build the foundation for evidence-based personalized medicine. This will require a partnership among researchers, clinicians, policy makers and regulators, and patients to design an integrated information network system that will be the basis for providing the right treatment for the right patient in the right place at the right time. In this review, we will discuss the salient points of the Act that specifically affect cancer research and care, as well as highlight opportunities for oncologists and researchers to play a primary role in developing a health care system that includes personalized medicine approaches that will in turn enhance the likelihood of achieving the goals and objectives of the health care reform act. Clin Cancer Res; 16(24); 5987–96. ©2010 AACR.

[1]  Gudmundur A. Thorisson,et al.  Genotype–phenotype databases: challenges and solutions for the post-genomic era , 2009, Nature Reviews Genetics.

[2]  Harold L. Moses,et al.  A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program , 2010 .

[3]  Chalapathy Neti,et al.  Rapid-learning system for cancer care. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Muin J Khoury,et al.  Comparative effectiveness research and genomic medicine: An evolving partnership for 21st century medicine , 2009, Genetics in Medicine.

[5]  P. LoRusso,et al.  Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed in the Right Direction? , 2010, Clinical Cancer Research.

[6]  C. Booth.  Evaluating Patient-Centered Outcomes in the Randomized Controlled Trial and Beyond: Informing the Future with Lessons from the Past , 2010, Clinical Cancer Research.

[7]  Kenneth H Buetow,et al.  An infrastructure for interconnecting research institutions. , 2009, Drug discovery today.

[8]  Lisa M. McShane,et al.  Effective Incorporation of Biomarkers into Phase II Trials , 2009, Clinical Cancer Research.

[9]  T. Fojo,et al.  Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much? , 2010, Clinical Cancer Research.

[10]  Asif Ahmad,et al.  Electronic Patient-Reported Data Capture as a Foundation of Rapid Learning Cancer Care , 2010, Medical care.

[11]  N. Meropol,et al.  Value and Cancer Care: Toward an Equitable Future , 2010, Clinical Cancer Research.

[12]  Andrew S. Boozary,et al.  The Commonwealth Fund , 1948, Nature.

[13]  Sowmya R. Rao,et al.  Use of electronic health records in U.S. hospitals. , 2009, The New England journal of medicine.

[14]  D. Makuc,et al.  Health, United States, 2009; with special feature on medical technology , 2010 .

[15]  Francis S Collins,et al.  The genome gets personal--almost. , 2008, JAMA.

[16]  Lawrence D. True,et al.  Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents , 2010, Clinical Cancer Research.

[17]  T. Yeatman,et al.  On the eve of personalized medicine in oncology. , 2008, Cancer research.

[18]  Bryan R Luce,et al.  Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change , 2009, Annals of Internal Medicine.

[19]  David Howard,et al.  Cancer treatment cost in the United States , 2010, Cancer.

[20]  F. Fincham,et al.  Mirror, mirror on the wall , 1996 .

[21]  E. Emanuel,et al.  Essential elements of a technology and outcomes assessment initiative. , 2007, JAMA.

[22]  Gary Natriello.  FOCUS , 1985, Digital-Age Innovation in Higher Education.

[23]  Timothy J. Yeatman,et al.  Proteomic Contributions to Personalized Cancer Care* , 2008, Molecular & Cellular Proteomics.

[24]  Susan Groshen,et al.  The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee , 2010, Clinical Cancer Research.

[25]  K. Davis,et al.  Mirror, Mirror on the Wall: How the Performance of the U.S. Health Care System Compares Internationally, 2010 Update , 2010 .

[26]  Larry Rubinstein,et al.  Randomized Phase II Designs , 2009, Clinical Cancer Research.

[27]  Patricia A. Ganz,et al.  From cancer patient to cancer survivor : lost in transition , 2006 .

[28]  Clayton M. Christensen,et al.  The Innovator's Prescription: A Disruptive Solution for Health Care , 2008 .

[29]  S. Tunis,et al.  Does comparative-effectiveness research threaten personalized medicine? , 2009, The New England journal of medicine.

[30]  S. Friend,et al.  Cancer Biomarkers—An Invitation to the Table , 2006, Science.

[31]  RobeRt Kelley,et al.  WHERE CAN $700 BILLION IN WASTE BE CUT ANNUALLY FROM THE U.S. HEALTHCARE SYSTEM? , 2009 .

[32]  C. Rudin,et al.  The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center , 2010, Clinical Cancer Research.

[33]  R. Snyderman,et al.  Perspective: Prospective health care and the role of academic medicine: lead, follow, or get out of the way. , 2008, Academic medicine : journal of the Association of American Medical Colleges.

[34]  Thomas J. Smith,et al.  Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small , 2010, Clinical Cancer Research.

[35]  K. Davis,et al.  Mirror, Mirror on the Wall Mirror, Mirror on the Wall How the Performance of the U.S. Health Care System Compares Internationally , 2010 .

[36]  C. Compton.  Getting to personalized cancer medicine , 2007, Cancer.